Home > Press > Irilliant Announces New Patent
Abstract:
Broad Claims Granted for Aerosol Synthesis of Nanomaterials
Irilliant, Inc., a developer of high-throughput manufacturing processes for nanomaterials, has further enhanced and protected its CAFS (Chemical Aerosol-Flow Synthesis) process with a soon-to-be-issued U.S. patent.
The patent, "Controlled synthesis of nanoparticles using continuous liquid-flow aerosol method," will include claims for large-scale production of high-quality nanoparticles from aerosol. Earlier patented processes were not suitable for large-scale production, nor did they result in products of equally high quality.
In Irilliant's CAFS process, liquid containing the precursors for the synthesis flows continuously through a sprayer, which in turn generates micron-sized droplets. These droplets serve as microreactors, and facilitate the creation of narrow-size distributed nanoparticles. Spraying large amounts of liquid in the reactor, facilitates manufacture of high-quality, surface-stabilized nanoparticles in large quantities. Ultrasonic or large scale industrial sprayers can be used to further enhance throughput. This configuration permits production of a higher quality product with a greater yield compared to previous methods.
Nanomaterials are used in a variety of emerging technologies including next generation photovoltaics, electronic displays, and lighting. "To sustain the explosive growth in these arenas, reliable, high volume production of nanomaterials at the proper pricing points will be needed," said Stephanos Papademetriou, Irilliant's President and CEO. "This addition to our IP portfolio gives us a tremendous competitive advantage. It also moves us closer to our goal of becoming a global leader in the production of a diverse array of quality nanomaterials at price points that are orders of magnitude lower than any other method of nanomaterial synthesis."
####
About Irilliant
Irilliant, Inc. is a leading nanosynthesis manufacturing company. By utilizing the company's patented CAFS technology, Irilliant can manufacture large quantities of a variety of nearly monodisperse colloidal solutions of nanomaterials (including CdSe, CdTe, CdSe/ZnS, CdS Quantum Dots, nanometals, and nano-oxides) at extraordinarily low cost.
The company specializes in post processing of nanomaterials for further functionalization and adaptation into intelligent devices. Areas of expertise include modification of polymers with nanosilver for enhanced antimicrobial activity, fluorescently encoded and magnetically enhanced microparticles, high-density binary code fluorescent markers, ultra-high magnetization superparamagnetic nanomagnets, and quantum dot fiber structures.
For additional information, please visit www.Irilliant.com
For more information, please click here
Contacts:
Irilliant, Inc.
Marketing Department
67 East Evelyn Avenue
Suite 5
Mountain View, CA 94041
Email Contact
Tel: (650) 575-4450
Copyright © Marketwire
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Materials/Metamaterials/Magnetoresistance
Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024
Focused ion beam technology: A single tool for a wide range of applications January 12th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||